Table 6.
Tumor antigen expression following treatment with tyrosinase vaccines and IL-2 on the single cohort trial
| Patient no. (response) | Site | Lesion growth | % Positive tumor cells* |
|||||
|---|---|---|---|---|---|---|---|---|
| Tyrosinase | gp100 | MART-1 | MHC I | HLA-DR | CD3† | |||
| 5 (MXR) | LN-1 | Regr‡ | 50 | 20 | 5 | >50 | 20 | 2+ |
| LN-2 | Stable | 5–50 | >50 | 0 | ND | 5–50 | 3+ | |
| Lung | Progr | 0 | 0 | 0 | 10–50 | 0 | 1+ | |
| Bowel | New | 0 | 0 | 0 | ND | ND | ND | |
| 7 (MR) | LN | Progr | >50 | >50 | >50 | 0 | 0 | 1+ |
| 8 (MXR) | LN | Progr | 0 | <5 | 0 | 5–50 | 5–50 | 3+ |
| 13 (MXR) | S.c. | New | >50 | >50 | >50 | 5–50 | <5 | 1+ |
| 19 (NR) | S.c. | Progr | 0 | 0 | 0 | >50 | >50 | 3+ |
*
Immunostaining of paraffin-embedded tissue sections.
†
Presence of CD3+ cells was scored on a 0 to 3+ scale.
‡
Regr, regressing; progr, progressing.